US 10,851,175 B2 · Anti-mesothelin antibody and composition comprising the same

Abstract

The present invention relates to an antibody specifically bound to mesothelin (MSLN), a nucleic acid encoding the antibody, a vector and a host cell including the nucleic acid, a method for producing the antibody, and a pharmaceutical composition for treating cancer or tumor including the antibody as an active ingredient. The antibody specifically bound to the mesothelin according to the present invention has high affinity and specificity to an antigen, such that it is possible to develop an antibody effectively usable for treatment or diagnosis of cancer or tumor diseases.

An antibody binding to mesothelin comprising

a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
9, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
10, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
11, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
12, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
13 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
14;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
15, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
16, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
17, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
18, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
19 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
20;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
21, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
22, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
23, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
24, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
25 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
26;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
27, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
28, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
29, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
30, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
25 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
26;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
60, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
61, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
62, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
63 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
64;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
65, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
66, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
69;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
65, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
66, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
70, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
69;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
71, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
72, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
62, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
73 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
74;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
75, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
76, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
77, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
78 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
79;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
80, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
81, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
62, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
82 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
83;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
84, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
85, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
86, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
78 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
87;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
65, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
66, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
117, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
118;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
65, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
66, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
119;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
65, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
66, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
117, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
120;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
121, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
66, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
69;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
122, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
66, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
69;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
123, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
124, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
69;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
125, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
66, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
69;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
65, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
126, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
69;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
122, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
66, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
119;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
123, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
124, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
120;
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
125, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
66, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
119;
or
a heavy chain variable region comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:
59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO:
65, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:
126, and a light chain variable region comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO:
67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO:
68 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:
119.

159 more elements

Anti-mesothelin antibody and composition comprising the same

Life of this patent

Anti-mesothelin antibody and composition comprising the same

Life of this patent

Abstract

Claims15